AB-CHMINACA is an
indazole-based
synthetic cannabinoid
Synthetic cannabinoids are a class of designer drug molecules that bind to the same receptors to which cannabinoids ( THC, CBD and many others) in cannabis plants attach. These novel psychoactive substances should not be confused with synth ...
. It is a potent
agonist
An agonist is a chemical that activates a receptor to produce a biological response. Receptors are cellular proteins whose activation causes the cell to modify what it is currently doing. In contrast, an antagonist blocks the action of the ago ...
of the
CB1 receptor (''K''
i = 0.78 nM) and
CB2 receptor (''K''
i = 0.45 nM) and fully substitutes for
Δ9-THC in rat discrimination studies, while being 16x more potent. Continuing the trend seen in other cannabinoids of this generation, such as
AB-FUBINACA and
AB-PINACA
AB-PINACA is a compound that was first identified as a component of synthetic cannabis products in Japan in 2012.
It was originally developed by Pfizer in 2009 as an analgesic medication.
AB-PINACA acts as a potent agonist for the CB1 recepto ...
, it contains a
valine
Valine (symbol Val or V) is an α-amino acid that is used in the biosynthesis of proteins. It contains an α- amino group (which is in the protonated −NH3+ form under biological conditions), an α- carboxylic acid group (which is in the deprotona ...
amino acid amide residue as part of its structure, where older cannabinoids contained a
naphthyl
Naphthalene is an organic compound with formula . It is the simplest polycyclic aromatic hydrocarbon, and is a white crystalline solid with a characteristic odor that is detectable at concentrations as low as 0.08 ppm by mass. As an aromati ...
or
adamantane residue.
Side effects
There have been a number of reported cases of seizures, deaths, and psychotic episodes in relation to this synthetic cannabinoid.
Legal status
In 2015, AB-CHMINACA became a
Schedule I Schedule 1 may refer to:
* Schedule I Controlled Substances within the US Controlled Substances Act
* Schedule I Controlled Drugs and Substances within the Canadian Controlled Drugs and Substances Act
* Schedule I Psychotropic Substances within th ...
controlled substance in the United States.
AB-CHMINACA is an
Anlage II controlled substance in Germany as of May 2015.
As of October 2015 AB-CHMINACA is a controlled substance in China.
AB-CHMINACA is illegal in Switzerland as of December 2015.
AB-CHMINACA is an illegal substance in Russian Federation.
See also
*
5F-AB-PINACA
5F-AB-PINACA is an indazole-based synthetic cannabinoid that is derived from a series of compounds originally developed by Pfizer in 2009 as an analgesic medication, and has been sold online as a designer drug.
5F-AB-PINACA has been reported t ...
*
5F-ADB
*
5F-AMB
*
A-CHMINACA
*
AB-FUBINACA
*
AB-CHFUPYCA
*
AB-PINACA
AB-PINACA is a compound that was first identified as a component of synthetic cannabis products in Japan in 2012.
It was originally developed by Pfizer in 2009 as an analgesic medication.
AB-PINACA acts as a potent agonist for the CB1 recepto ...
*
ADB-CHMINACA
*
ADB-FUBINACA
*
ADB-PINACA
*
ADBICA
*
APICA
*
APINACA
*
MDMB-CHMICA
*
MDMB-CHMINACA
*
MDMB-FUBINACA
*
PX-3
PX-3 (also known as APP-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of ''K''i = 47.6 nM and was originally developed by Pfizer in 2009 as an analgesic
...
References
{{Cannabinoidergics
Cannabinoids
Designer drugs
Indazolecarboxamides
Cyclohexyl compounds